Cytokine and Metabolomic Signatures of Mepolizumab Response Across Upper and Lower Airway Compartments in Severe Eosinophilic Asthma: An Exploratory Analysis

<b>Background</b>: Mepolizumab improves asthma control in severe eosinophilic asthma (SEA). However, its multidimensional effects on airway and systemic biomarkers are still incompletely understood. <b>Methods</b>: In this prospective study, 15 SEA patients were evaluated at baseline (T<sub>0</sub>), 6 (T<sub>6</sub>), and 12 months (T<sub>12</sub>) after starting mepolizumab. Lung function, FeNO values, asthma control, blood eosinophil count (BEC), cytokines, and metabolomic profiles (<sup>1</sup>H-NMR) were evaluated in serum, nasal secretions, and exhaled breath condensate (EBC). Univariate and multivariate (PCA, OPLS-DA) analyses were performed. <b>Results</b>: Mepolizumab reduced exacerbations, from a median of 2 at T<sub>0</sub> to 0 at both T<sub>6</sub> (<i>p</i> = 0.001) and T<sub>12</sub> (<i>p</i> = 0.003). ACT improved from 18.7 ± 4.7 at baseline to 23.0 ± 2.8 at T<sub>6</sub> (<i>p</i> = 0.026) and 23.4 ± 3.3 at T<sub>12</sub> (<i>p</i> = 0.032), while FEV<sub>1</sub> increased by 270 mL at T<sub>6</sub> (<i>p</i> = 0.032) and remained stable at T<sub>12</sub>. Median BEC decreased from 450.0 (350.0-560.0) to 65.0 (50.0-87.5) cells/μL at T<sub>6</sub> and to 50.0 (35.0-160.0) at T<sub>12</sub> (<i>p</i> < 0.001), while FeNO showed a non-significant downward trend. IL-13 significantly decreased in serum and nasal secretions at T<sub>6</sub> and T<sub>12</sub>, while IL-5 increased in nasal secretions at both timepoints and remained unchanged in serum. IL-2 showed opposite trends in serum and nasal samples, whereas GM-CSF and IFN-γ increased in nasal secretions at T<sub>12</sub>. Metabolomic profiling suggested compartment-specific changes, with decreased short-chain alcohols in EBC, increased amino acids in nasal secretions and serum at T<sub>6</sub>, and elevated pyruvate in serum at T<sub>12</sub>, although none reached statistical significance in univariate analysis. <b>Conclusions</b>: Mepolizumab induced consistent clinical, immunologic, and metabolic changes across compartments, supporting the use of integrated cytokine and <sup>1</sup>H-NMR metabolomic profiling as a complementary approach for response assessment in SEA.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2025-11-10
DOI
https://doi.org/10.3390/ph18111704
Citations
1
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
1.16
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cytokine and Metabolomic Signatures of Mepolizumab Response Across Upper and Lower Airway Compartments in Severe Eosinophilic Asthma: An Exploratory Analysis

Claudio Candia, Nicolino Ambrosino, Isabella Gnemmi, Martina Zappa et al.
1 citations
Pharmaceuticals
Asthma and respiratory diseases
1.16
article

Cytokine and Metabolomic Signatures of Mepolizumab Response Across Upper and Lower Airway Compartments in Severe Eosinophilic Asthma: An Exploratory Analysis

Claudio Candia, Nicolino Ambrosino, Isabella Gnemmi, Martina Zappa, Pasquale Ambrosino, Dina Visca, Andréa Motta, Antonino Di Stefano
article en
1 citations

Abstract

<b>Background</b>: Mepolizumab improves asthma control in severe eosinophilic asthma (SEA). However, its multidimensional effects on airway and systemic biomarkers are still incompletely understood. <b>Methods</b>: In this prospective study, 15 SEA patients were evaluated at baseline (T<sub>0</sub>), 6 (T<sub>6</sub>), and 12 months (T<sub>12</sub>) after starting mepolizumab. Lung function, FeNO values, asthma control, blood eosinophil count (BEC), cytokines, and metabolomic profiles (<sup>1</sup>H-NMR) were evaluated in serum, nasal secretions, and exhaled breath condensate (EBC). Univariate and multivariate (PCA, OPLS-DA) analyses were performed. <b>Results</b>: Mepolizumab reduced exacerbations, from a median of 2 at T<sub>0</sub> to 0 at both T<sub>6</sub> (<i>p</i> = 0.001) and T<sub>12</sub> (<i>p</i> = 0.003). ACT improved from 18.7 ± 4.7 at baseline to 23.0 ± 2.8 at T<sub>6</sub> (<i>p</i> = 0.026) and 23.4 ± 3.3 at T<sub>12</sub> (<i>p</i> = 0.032), while FEV<sub>1</sub> increased by 270 mL at T<sub>6</sub> (<i>p</i> = 0.032) and remained stable at T<sub>12</sub>. Median BEC decreased from 450.0 (350.0-560.0) to 65.0 (50.0-87.5) cells/μL at T<sub>6</sub> and to 50.0 (35.0-160.0) at T<sub>12</sub> (<i>p</i> < 0.001), while FeNO showed a non-significant downward trend. IL-13 significantly decreased in serum and nasal secretions at T<sub>6</sub> and T<sub>12</sub>, while IL-5 increased in nasal secretions at both timepoints and remained unchanged in serum. IL-2 showed opposite trends in serum and nasal samples, whereas GM-CSF and IFN-γ increased in nasal secretions at T<sub>12</sub>. Metabolomic profiling suggested compartment-specific changes, with decreased short-chain alcohols in EBC, increased amino acids in nasal secretions and serum at T<sub>6</sub>, and elevated pyruvate in serum at T<sub>12</sub>, although none reached statistical significance in univariate analysis. <b>Conclusions</b>: Mepolizumab induced consistent clinical, immunologic, and metabolic changes across compartments, supporting the use of integrated cytokine and <sup>1</sup>H-NMR metabolomic profiling as a complementary approach for response assessment in SEA.

PharmaceuticalsVol. 18(11)
University of Insubria (IT), Istituti Clinici Scientifici Maugeri (IT), Federico II University Hospital (IT), National Research Council (IT), University of Palermo (IT)
Openalex Percentile: Top 16%
Asthma and respiratory diseases
1.16
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.